Dear Dr. Knipher:

Please refer to your supplemental new drug applications dated February 05, 2003, received February 06, 2003, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Prevacid® (lansoprazole) Delayed-Release Capsules, PREVACID® SoluTab™ (lansoprazole) Delayed-Release Orally Disintegrating Tablet, and Prevacid® (lansoprazole) for Delayed-Release Oral Suspension.

This supplemental new drug application provides for the revision of the ADVERSE REACTIONS section, Post-Marketing Adverse Events sub-section of the package insert.

We completed our review of these applications and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the agreed upon labeling text listed below. Accordingly, these applications are approved, effective on the date of this letter.

Postmarketing

On-going Safety Surveillance: Additional adverse experiences have been reported since lansoprazole has been marketed. The majority of these cases are foreign-sourced and a relationship to lansoprazole has not been established. Because these events were reported voluntarily from a population of unknown size, estimates of frequency cannot be made. These events are listed below by COSTART body system.

*Body as a Whole* - anaphylactoid-like reaction; *Digestive System* - hepatotoxicity, pancreatitis, vomiting; *Hemic and Lymphatic System* - agranulocytosis, aplastic anemia, hemolytic anemia, leukopenia, neutropenia, pancytopenia, thrombocytopenia, and thrombotic thrombocytopenic purpura; *Skin and Appendages* – severe dermatologic reactions including erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis (some fatal); *Special Senses* - speech disorder; *Urogenital System* - urinary retention.

The final printed labeling (FPL) must be identical to the submitted labeling (package insert submitted February 05, 2003).

Please submit the FPL electronically according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format – NDA (January 1999). Alternatively, you may submit 20 paper copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated “FPL for approved supplements NDA 20-406/S-055, NDA 21-428/S-001, and NDA 21-281/S-009.” Approval of this submission by FDA is not required before the labeling is used.
In addition, submit three copies of the introductory promotional materials that you propose to use for this product. Submit all proposed materials in draft or mock-up form, not final print. Send one copy to the Division of Gastrointestinal and Coagulation Drug Products and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-42
Food and Drug Administration
5600 Fishers Lane
Rockville, MD 20857

If you issue a letter communicating important information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Melissa Hancock Furness, Regulatory Project Manager, at (301) 827-7450.

Sincerely,

{See appended electronic signature page}

Robert L. Justice, M.D., M.S.
Director
Division of Gastrointestinal & Coagulation Drug Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/
---------------------
Robert Justice
8/5/03 04:26:32 PM